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Background: The human COL11A1 gene has been shown to be up-regulated in stromal cells of colorectal tumours,
but, so far, the immunodetection of procollagen 11A1, the primary protein product of COL11A1, has not been
studied in detail in human colon adenocarcinomas. Some cancer-associated stromal cells seem to be derived from
bone marrow mesenchymal cells; the expression of the COL11A1 gene and the parallel immunodetection of
procollagen 11A1 have not been evaluated in these latter cells, either.
Methods: We used quantitative RT-PCR and/or immunocytochemistry to study the expression of DES/desmin, VIM/
vimentin, ACTA2/αSMA (alpha smooth muscle actin) and COL11A1/procollagen 11A1 in HCT 116 human colorectal
adenocarcinoma cells, in immortalised human bone marrow mesenchymal cells and in human colon
adenocarcinoma-derived cultured stromal cells. The immunodetection of procollagen 11A1 was performed with the
new recently described DMTX1/1E8.33 mouse monoclonal antibody. Human colon adenocarcinomas and non-malignant
colon tissues were evaluated by immunohistochemistry as well. Statistical associations were sought between
anti-procollagen 11A1 immunoscoring and patient clinicopathological features.
Results: Procollagen 11A1 was immunodetected in human bone marrow mesenchymal cells and in human
colon adenocarcinoma-associated spindle-shaped stromal cells but not in colon epithelial or stromal cells of
the normal colon. This immunodetection paralleled, in both kinds of cells, that of the other mesenchymal-
related biomarkers studied: vimentin and alpha smooth muscle actin, but not desmin. Thus, procollagen 11A1+
adenocarcinoma-associated stromal cells are similar to “activated myofibroblasts”. In the series of human colon
adenocarcinomas here studied, a high procollagen 11A1 expression was associated with nodal involvement
(p = 0.05), the development of distant metastases (p = 0.017), and advanced Dukes stages (p = 0.047).
Conclusion: The immunodetection of procollagen 11A1 in cancer-associated stromal cells could be a useful
biomarker for human colon adenocarcinoma characterisation.
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A wealth of studies have reported that the COL11A1 hu-
man gene, coding for the α1 chain of procollagen and
mature collagen of type XI, which is an extracellular
minor fibrillar collagen, is up-regulated in some human
tumours and in mesenchymal-derived tumour cell lines
[1-32], as well as in mesenchymal stem cells and osteo-
blasts [33-35].
Collagen polypeptides are synthesized as procollagens,
with the N- and C-propeptides at the ends of the proto-
typical collagen triple helix. Upon secretion, the propep-
tides are excised and then the mature collagen molecules
assemble in fibrils.
In tumours, the expression of the COL11A1 gene is
currently associated to a fibroblast-like stromal pheno-
type [12,19] but the origin and nature of the cells which
produce procollagen and collagen 11A1 remain contro-
versial to some extent [26].
The so-called cancer-associated stromal cells, resulting
from the desmoplastic reaction which accompanies the
development of human invasive carcinomas, comprise
cells of different types, and are at least in part derived
from mesenchymal progenitors and local resident cells. It
is also well-established that TGF-β1 in cancer promotes
the activation of cancer-associated stromal cells [36].
For the present study, we set out to verify the expression
of the COL11A1 gene, by quantitative RT-PCR in TGF-
β1-exposed epithelial human colorectal HCT 116 cells
and Immortalised Human Bone Marrow Mesenchymal
Cells (hTERT-HMCs); and the expression of procollagen
11A1 by immunocytochemistry (ICC)/immunohisto-
chemistry (IHC), using the DMTX1/1E8.33 monoclo-
nal antibody (mAb) [37], on those cell cultures as well
as on biopsies of human colon adenocarcinomas. Concur-
rently, we studied the expression of DES/desmin,VIM/
vimentin and ACTA2/αSMA (alpha smooth muscle actin)
as mesenchymal (myofibroblast)/stromal markers.
Within the N-propeptide of human procollagen 11A1,
it is the so-called “variable region”, the most divergent
amino acid sequence stretch among different procollagens.
The DMTX1/1E8.33 mAb recognises an epitope in the
YNYGTMESYQTEAPR amino acid stretch within the
variable region of human procollagen 11A1 [37].Methods
Cell cultures
Ascorbate is a well-known inducer of the synthesis of some
collagens [38,39]; thus, to favour the expression of procol-
lagen 11A1, cells were habitually cultured with this supple-
ment. Since TGF-β1 levels are increased in the serum of
patients with invasive carcinomas [40], we chose to analyse
its effects after continued and protracted exposure of cell
cultures to this cytokine.The human colorectal adenocarcinoma HCT 116
(CCL-247) cell line, derived from a primary tumour,
was obtained from the American Type Culture Collec-
tion (ATCC) and cultured in DMEM, supplemented with
1 mM sodium pyruvate (Biochrom), 2 mM L-glutamine
(Biochrom), 1X non-essential amino acids (Biochrom),
10% foetal bovine serum (Biochrom), and ascorbate 2-
phosphate (37.5 μg/ml) (Wako Chemicals).
Immortalised Human Bone Marrow Mesenchymal
Cells-hTERT (hTERT-HMCs) were obtained from Applied
Biological Materials (ABM) Inc., Richmond, BC, Canada
(Cat. No. T0523), and grown in T25 ECM-coated flasks in
Prigrow II medium (ABM, Cat. No. TM002), with the
addition of 10% foetal bovine serum, 1 μM hydrocortisone
(Sigma) and ascorbate 2-phosphate (37.5 μg/ml) (Wako
Chemicals).
For TGF-β1 induction, media were further supplemented
with 10 ng/ml of recombinant TGF-β1 (Peprotech). The
medium was replaced every 3–4 days and the cells were
cultured for at least 15 days.
All the cultures were carried out in a humidified atmos-
phere of 5% CO2 in air at 37°C.
Culture passages and cell collections were done with
trypsin/EDTA 0.05%/0.02% (Biochrom). Three different
harvests from each cell culture type were obtained; for
Q-RT-PCR, fresh cell pellets were kept at −80°C.Colon adenocarcinoma stromal cells isolation and culture
Fresh human tissue samples were procured after written
informed consent of the patients and approval by the
Principality of Asturias Ethics Committee of Clinical
Research, Oviedo, Spain.
Short-term cultures of colon adenocarcinoma stromal
cells were carried out, as previously described [41], from
samples of tumoral sites, avoiding necrotic areas. A sam-
ple from the operating theatre was directly transferred
to a sterile tube containing DMEM culture medium (Gibco,
Invitrogen), supplemented with vancomycin (40 μg/ml) and
amikacin (40 μg/ml) (Normon Laboratories, Madrid,
Spain), and stored for 24 hours at 4°C.
After three washings with phosphate buffer saline
(PBS), the sample was cut into several small fragments.
These fragments were first incubated with collagenases
(Type I 2 mg/ml, Sigma) for 1.5 hours and then centri-
fuged to eliminate supernatant; subsequently, the pellet
was subjected to a second incubation in trypsin/EDTA
for 30 min. After digestion, the cells were again collected
in a pellet, resuspended in DMEM culture medium, sup-
plemented with 10% foetal bovine serum, L-glutamine and
penicillin/streptomycin, transferred to T-flasks and culti-
vated in 5% CO2 at 37°C.
Stromal cell cultures were stable up to 5–6 passages
before going into senescence. The purity of these stromal
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staining for vimentin.
Q-RT-PCR
For normalisation of data, quantitative RT-PCR of DES,
VIM, ACTA2 and COL11A1 mRNA, and PUM1, RPL10,
and GAPDH mRNA was performed using the BioMark™
HD System of the Fluidigm technology (Fluidigm, San
Francisco, USA).
Briefly, total RNA was isolated from pooled cell cul-
tures, kept at −80°C, with the RNeasy Mini kit (Qiagen).
cDNA was synthesized from 100 ng of RNA from each
sample, using the AffinityScript Multiple Temperature
cDNA Synthesis kit (Agilent Technologies). A pre-
amplification was carried out, applying the QIAGEN®
Multiplex PCR Kit and the pool of all the 20x TaqMan®
Gene Expression Assays. Real time Q-PCR reactions
were carried out with the TaqMan Universal PCR Master
Mix kit (Applied Biosystems). Further details, according
to Applied Biosystems’ recommendations, are in Table 1.
Data were normalised by applying the ΔCt method,
after PCR efficiency corrections. These analyses were
performed by Progenika Biopharma, S.A., Derio, Spain.
Three independent samples (n =3) of different cell har-
vests of each cell type were studied. Data are presented
as mean and SEM. For each gene, differences between
cell culture expressions were analysed by a two-tailed
unpaired t-test. A P value <0.01 was considered statistically
significant.
Immunohistochemistry (IHC)
For immunohistochemical techniques, a cohort of 51 pa-
tients with colon adenocarcinoma and 6 patients diagnosed
with incipient bowel infarction were collected from the
Archive of the Pathology Department, Asturias Central
University Hospital, with the Principality of Asturias
Ethics Committee of Clinical Research, Oviedo, Spain,
approval for guidelines on ethical procedures. The sam-
ples had been fixed with 10% formaldehyde for 24 h and
embedded in paraffin.Table 1 Assays selected and PCR conditions for Q-RT-PCR
of mRNA analysis
Gene Assay ID
COL11A1 Hs01097664_m1
GAPDH Hs02758991_g1
PUM1 Hs004472881_m1
RPL10 Hs00749196_s1
DES Hs00157258_m1
ACTA2 Hs00426835_g1
VIM Hs00185584_m1
PCR conditions were: 50°C – 2 min; 95°C – 10 min; and 40 amplification cycles:
95°C – 15 sec and 60°C – 1 min.Three-μm thick tissue sections were stained with
Hematoxylin and Eosin (H&E) for histological examin-
ation. Antigen retrieval was performed by heating in
PTLink (DakoCytomation, Denmark) in buffer solution
at high pH for 20 minutes. Endogenous peroxidase ac-
tivity was blocked with Peroxidase Blocking Reagent
(DakoCytomation, Denmark) for 5 minutes. After that,
samples were first incubated at 37°C with the primary
antibodies described in Table 2. Subsequently, the EnVision
system (HRP Flex) (DakoCytomation) was applied for
30 minutes at room temperature. Then, the samples were
stained with DAB (3-3′-Diaminobenzidine) (DakoCytoma-
tion, Denmark) for 10 minutes, counterstained for 10 mi-
nutes with hematoxylin (DakoCytomation), dehydrated and
mounted in Entellan® (Merck, Germany). Finally, the
stained tissue sections were studied and photographed
(40× objective) under a light microscope (Nikon -
Eclipse 80i).
Immunocytochemistry (ICC)
Cells were fixed in 10% formaldehyde for 10 minutes in
the chamber slide (BD Falcon™, ref. 354114). Endogen-
ous peroxidase activity was blocked with Peroxidase
Blocking Reagent (DakoCytomation, Denmark) for 5 minutes.
Permeabilization step was performed adding wash buffer
1× (DakoCytomation, Denmark) which contains 0.05 mol/L
Tris/HCl, 0.15 mol/L NaCl, 0.05% Tween-20 [41]. Primary
antibodies were applied, as described in Table 2, at room
temperature. After that, slides were incubated with the
EnVision system (HRP Flex) for 10 minutes at room
temperature. Then, the samples were visualised with DAB
for 5 minutes, and counterstained with hematoxylin for
5 minutes. Finally, the stained slides were dehydrated,
mounted, studied and photographed as above.
Immunohistochemistry assessment
Specimens were assessed by three observers (JAG, CGP
and CGR), following these criteria: procollagen 11A1 im-
munostaining was evaluated according to the cytoplasmatic
signal as the product of two parameters: extent of immuno-
reactivity, which was evaluated in the most densely stained
area (hot spot) under the 20× objective and scored on a
0–3 scale, according to the proportion of positive fibro-
blasts: (0) 0%; (1) <10%; (2) 10-50% and (3) >50%; and
granularity in the cytoplasm, evaluated as dispersed vs.
confluent (1 and 2 points, respectively), with the 40×
objective. Immunoscore values ranged from 0 to 6.
Adjacent non-malignant tissue was used as a negative
control.
Statistical analysis
The experimental results were tested for significance
employing the χ2 test (with Yates’ correction, when ap-
propriate). The statistical analysis was carried out with
Table 2 Antibodies used in IHC/ICC analysis
Primary antibodies (species) Clone Commercial reference Dilution Incubation time (min)
Procollagen 11A1 (mAb) 1E8.33 DMTX1/Oncomatrix, Spain 1:400 30
Desmin (mAb) D33 Dako, Denmark R-t-U 20
α-SMA (mAb) 1A4 Dako, Denmark R-t-U 20
Vimentin (pAb) C-20 Santa Cruz Biotech, Germany 1:600 10
mAb: Mouse monoclonal antibody.
pAb: Rabbit polyclonal antibodies.
R-t-U: Ready-to-Use.
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IL). All tests were two-sided and p < 0.05 values were con-
sidered statistically significant.
Results
Study of human cell cultures
So far, we are not aware of any human colorectal cell line
in which the expression of the COL11A1 gene has been re-
ported, but we had observed that primary cultures of bone
marrow-derived human mesenchymal cells, expressed
COL11A1/procollagen 11A1, especially after long ex-
posure (≥15 days) to TGF-β1 (data not shown).
We have presently studied the well-known epithelial
human colorectal HCT 116 cell line as a negative con-
trol for the expression of the mesenchymal DES, VIM,
ACTA2 and COL11A1 genes in relation to their expres-
sion by cultured immortalised hTERT-HMCs. The ex-
pression of the DES, VIM, ACTA2 and COL11A1 genes
was analysed by Q-RT-PCR; the immunodetection of
desmin, vimentin, αSMA and procollagen 11A1 was per-
formed by ICC.Figure 1 Q-RT-PCR data of DES, VIM, ACTA2 and COL11A1 mRNA expr
immortalised hTERT-HMCs, both after long exposure to ascorbate 2-p
PUM1, RPL10, and GAPDH mRNA expression (n =3; mean ± SEM; *P <0.05, *According to the normalised Q-RT-PCR data we have
obtained (Figure 1), TGF-β1-activated hTERT-HMCs did
not express DES mRNA, but noticeable amounts of VIM,
ACTA2 and COL11A1 mRNA. The corresponding protein
expression was confirmed by ICC (Figure 2). An average
of 20% of these cells in cultures exposed to TGF-β1
showed a granular pattern of intracytoplasmic immu-
nostaining of procollagen 11A1. None of these markers
was expressed by the HCT 116 cells, but certain levels
of DES.
Examination of human tissues
Fifty one paraffin-embedded archival samples of human
colon adenocarcinomas were examined by IHC with the
DMTX1/1E8.33 mAb; all cases presented adjacent non-
malignant tissue as control. Six cases of incipient bowel
infarction were similarly studied. Table 3 shows the
characteristics of patients and samples, and their anti-
procollagen 11A1 immunoscores, evaluated as described
in Methods; as shown, these immunoscores ranged from
0 to 6. A more detailed description of these characteristicsession in cell cultures of the HCT 116 cell line and in
hosphate and TGF-β1. The data were normalised in relation to
*P <0.01).
Figure 2 Representative immunostaining of cultured immortalised hTERT-HMCs after long exposure to ascorbate 2-phosphate and
TGF-β1. A) Procollagen 11A1 B) Desmin, C) αSMA and D) Vimentin. Scale bar 50 μm (400×).
Galván et al. BMC Cancer 2014, 14:867 Page 5 of 12
http://www.biomedcentral.com/1471-2407/14/867is in Additional file 1. In three of these 51 diagnosed adeno-
carcinoma cases, no procollagen 11A1 staining could be
detected, in spite of extensive re-examination. Procollagen
11A1 was neither immunodetected in the adjacent non-
malignant tissues nor in the infarction cases.
Figure 3 shows representative procollagen 11A1 im-
munostaining patterns (panels A, B, C and D); only a
granular cytoplasmic staining of peritumoral spindle-
shaped fibroblast-like stromal cells was observed. This
granularity was either dispersed, with a few granules in
the cytoplasm of stromal cells (panel G) or frankly con-
fluent (panel H). No staining was observed on specimens
of bowel ischemia (panel E) or on non-malignant tissues
(panel F).
Figure 4 shows a representative immunostaining of an
adenocarcinoma specimen with a procollagen 11A1
immunoscore of 6. As shown on panel A, only peritu-
moral stromal cells were stained with the anti-procollagen
11A1 mAb; besides, these cells seemed to be positive for
αSMA (C) and vimentin (D), but negative for desmin (B).
This immunostaining pattern was reproduced (panels E, F,
G and H) in stromal cells cultured from fresh specimens
of the same patient.
Association between procollagen 11A1 expression and
clinicopathological features
For statistical purposes, some variables (age at diagnosis,
tumour size, anti-procollagen 11A1 immunostaining) weredivided into 2 groups, taking the median score value as a
cut-off point (Table 4). Patients diagnosed with ischemia
were excluded from this analysis.
9/12 patients that had developed distant metastases at
diagnosis and 15/27 patients with advanced Dukes stages
were associated with high procollagen 11A1 expression
(p = 0.017 and p = 0.047, respectively). The same can be
observed for 15/26 patients with nodes affected, how-
ever, only with a trend towards significance (p = 0.059).
Discussion
We have presently shown, extending our previous obser-
vations [42], that procollagen 11A1, as a protein expres-
sion product of the COL11A1 gene, is immunodetected
in stromal cells of human colon adenocarcinoma. By
contrast, and contrary to a previous report [15], we have
never observed immunodetection of procollagen 11A1
in epithelial cells of normal colon tissue or colon adeno-
carcinoma with the DMTX1/1E8.33 mAb. This immu-
nodetection was observed in 48 of the 51 cases studied.
Three cases (5.9%), which were classified under the same
criteria as the rest of the cases examined as conventional
adenocarcinomas with desmoplastic reaction, did not
stain; so far, we have not identified in them any charac-
teristics to which this negative immunostaining could be
associated. Except for the report of Fischer et al. [1] who
did not find either the expression of COL11A in 5 out of
15 (33.3%) colonic carcinomas analysed, we are not aware
Table 3 Patient characteristics (N = 51)*
Frecuency N (%)
Gender Female 19 37.3
Male 32 62.7
Age (years) Median (range) 70 (31–85)
Tumor size (cm) Median (range) 3.7 (0.5 -
11)
Localization Ascending
colon
21 41.2
Descending
colon
8 15.7
Sigmoid 22 43.1
Differentiation Well
differentiated
19 37.3
Moderately
differentiated
28 54,9
Poorly
differentiated
4 7.8
T T1 3 5,9
T2 7 13.7
T3 28 54.9
T4 13 25.5
N pN0 25 49.0
pN1 26 51.0
M M0 39 76.5
M1 12 23.5
TNM staging I 8 15,7
IIA 12 23,5
IIB 4 7,8
IIIA 1 2,0
IIIB 9 17,6
IIIC 5 9,8
IV 12 23,5
Dukes staging A 8 15,7
B 16 31,4
C 15 29,4
D 12 23,5
Anti-procollagen 11A1
immunostaining by score
0 3 5.9
1 12 23.5
2 13 25.5
3 4 7.8
4 6 11.8
6 13 25.5
Anti-procollagen 11A1
immunostaining
Low (≤2) 28 54.9
(Median =2) High (>2) 23 45.1
(*) Patients diagnosed with colon adenocarcinoma.
Patients diagnosed with ischemia were excluded.
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adenocarcinomas expressing the COL11A1 gene; this as-
pect should be studied in detail.
We have very recently reported that procollagen 11A1+
cancer-associated stromal cells of pancreatic ductal adeno-
carcinoma co-express αSMA, and/or vimentin, and/or des-
min in different proportions [41]. We have now confirmed,
by Q-RT-PCR and IHC/ICC, the stromal expression of hu-
man procollagen 11A1 in colon adenocarcinoma. Although
not formally proven, procollagen 11A1+ colon adenocar-
cinoma stromal cells, being spindle-shaped, seem to sim-
ultaneously express alpha smooth muscle actin and
vimentin, but no desmin; these traits confer to them a
myofibroblast-like phenotype rather than a pericyte one
[43]. While in the desmoplastic component of hepatocel-
lular carcinomas and pancreatic ductal adenocarcinomas
there is a significant contribution of desmin + stellate cells,
this is not the case in colon adenocarcinomas. As normal
resident intestinal myofibroblasts are not immunoreactive
to the DMTX1/1E8.33 mAb, these procollagen 11A1+
desmin− colon adenocarcinoma stromal cells could be a
type of “activated myofibroblasts”.
We have also shown that a fraction of cultured immor-
talised HMCs, after long exposure to TGF-β1, exhibit a
very similar phenotype to the described above for cancer-
associated stromal cells. It is intriguing that only as much
as 20% of these cultured cells express procollagen 11A1;
this aspect warrants further analysis as well as the global
genotype and phenotype of procollagen 11A1+ cells.
It has been reported that human bone marrow-derived
mesenchymal cells may differentiate in vitro to fibroblast/
myofibroblast-like cells under certain conditions, such as
coculture with human colon carcinoma cells and TGF-β1,
or prolonged exposure to conditioned medium from
MDA-MB-231 breast cancer cells; these fibroblast/
myofibroblast-like cells are able to promote tumour
growth both in vitro and in vivo [36,44-47]. As the
phenotype of procollagen 11A1+ “myofibroblasts” from
colon adenocarcinoma resembles that of cultured TGF-
β1-activated human bone marrow mesenchymal cells, all
these observations add support to the tenet that at least
some cancer-associated stromal cells, such as the procolla-
gen 11A1+ ones, could be bone marrow-derived mesen-
chymal cells. Altogether, we may suggest that procollagen
11A1 could be expressed by a more specialized subpopu-
lation among “activated myofibroblasts”.
Halsted et al. [14] reported the cytoplasmic, stromal
and vascular immunostaining of both normal and malig-
nant human breast tissues with polyclonal antisera to spe-
cific regions of N-terminal domains of human procollagen
11A1. Vargas et al. [30] immunodetected collagen 11A1
in the normal epithelium of human breast and Wu et al.
[31] performed it in some human ovarian cancer cell lines,
after applying another antibody preparation. Moreover,
Figure 3 Representative procollagen 11A1 immunostaining in colon adenocarcinoma. A) Score 1, B) Score 2; C) Score 4; D) Score 6. Arrow
heads point to stained peritumoral stromal cells. E) Bowel ischemia; F) Non-malignant tissue. Scale bar 50 μm (400X). G) Dispersed granularity
and H) Confluent granularity. Scale bar 20 μm (1000×).
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Figure 4 Representative immunostaining of a colon adenocarcinoma: A) Procollagen 11A1 (immunoscore 6), B) Desmin, C) αSMA and
D) Vimentin (these images were taken from the same area of serial sections; and of cultured stromal cells from the same case:
E) Procollagen 11A1, F) Desmin, G) αSMA and H) Vimentin. Scale bar 50 μm (400×).
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Table 4 Association between procollagen 11A1 expression and clinicopathological features
Anti-procollagen 11A1 immunostaining (Median =2)
Low (≤2) High (>2) p
Age (Median 70 years) ≤ 70 years 13 14 0.304
> 70 years 15 9
Gender Female 18 14 0.802
Male 10 9
Localization Ascending colon 9 12 0.260
Descending colon 6 2
Sigmoid 13 9 0.200
Tumor size (Median = 3.7 cm) Small ≤3.7 cm 12 14
Large >3.7 cm 16 9 0.370
Differentiation Well differentiated 12 7
Moderately differentiated 15 13
Poorly differentiated 1 3
T T1-T2 8 2 0.075
T3-T4 20 21
N Absent 17 8
Present 11 15 0.059
M Absent 25 14
Present 3 9 0.017
Stage grouping I 7 1 0.141
IIA 7 5
IIB 2 2
IIIA 1 0
IIIB 6 3
IIIC 2 3
IV 3 9
Dukes staging A 7 1
B 9 7
C 9 6 0.047
D 3 9
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in relation to the kind of cells in which COL11A1
mRNA has been detected. While in situ hybridization
studies have spotted its detection only in stromal cells
[1,17], another study, based on differentially expressed
gene analyses by GeneChip hybridization, has pointed
to the over-expression of COL11A1 mRNA in tumour
epithelia [13]; very recently, Cheon et al. [48] have re-
ported, also through in situ hybridization and immu-
nohistochemistry with the DMTX1/1E8.33 mAb of
serous ovarian cancer, that “COL11A1 expression was
confined to intra/peritumoral stromal cells and rare
foci of tumor epithelial cells”.
In our experience, the immunodetection of procolla-
gen 11A1 with the DMTX1/1E8.33 mAb has never been
observed in normal epithelial, vascular or stromal cellsbut in cancer-associated stromal cells; immunochemistry
discrepancies between our observations and those above
mentioned may be attributed to the different fine specifi-
city of the applied antibody preparations. Besides this,
transcription profiling studies of human colon biopsies
obtained from active and inactive areas of ulcerative col-
itis and Crohn’s disease, compared with samples from
infectious colitis and healthy controls, have shown that
there are no differences in the expression levels of the
COL11A1 gene between any of the above referred to
conditions [49-53]. COL11A1/procollagen 11A1 expres-
sion is mostly absent in benign inflammatory processes
such as breast sclerosing adenosis [16,54], chronic pan-
creatitis [41], and diverticulitis (our own observations;
data not shown), and is rather low in familial adenomatosis
polyposis adenomas [1,2]. Thus, the in vivo up-regulation
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of cancer-associated stromal cells.
In this study, high procollagen 11A1 immunostaining
was associated with clinicopathological variables such as
lymph node involvement, advanced Dukes stages and
presence of distant metastases. These results go according
to the role of COL11A1 in promoting carcinoma aggres-
siveness and progression [11,17,20,30,31,48,55-57].
Conclusions
Based on its high specificity, our observations stress once
more the usefulness of the DMTX1/1E8.33 mAb for can-
cer research, and the clinical significance of procollagen
11A1 as a very valuable biomarker to characterise cancer-
associated stromal cells and to evaluate human colon
adenocarcinomas.
Additional file
Additional file 1: Detailed description of patients and their
clinicopathological characteristics.
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